Main navigation | Main content
New technologies delivered to your inbox Subscribe
20120271 – A new class of oligonucleotides can be used to treat cardiomyopathy. The short, protein-interacting DNAs and RNAs (SPIDRs) are designed to selectively bind to phospholamban (PLN), a compound that inhibits SERCA, which is a necessary function for cardiac health. Results show that ssDNA and RNA interact strongly with PLN, thereby inhibiting its effect on SERCA. Furthermore, the length... Read More